Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi

Next Previous
Trial Profile

A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Voriconazole; Voriconazole
  • Indications Aspergillosis; Invasive bronchopulmonary aspergillosis; Mycoses; Zygomycosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SECURE
  • Sponsors Astellas Pharma; Basilea Pharmaceutica

    • Most Recent Events

    • 14 Dec 2021 Results Post-Hoc Analysis from the VITAL and SECURE, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 25 Oct 2020 Results of post-hoc analysis of this trial, presented at the IDWeek 2020.
    • 02 May 2019 According to an AVIR Pharma Inc media release, Health Canada's approval of Cresemba was based on data from two Phase 3 clinical trials in adult patients with invasive fungal infections - SECURE and VITAL trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top